This study was a pragmatic, multicentre, phase 3, double-blind, randomised controlled trial conducted in England and Wales.
It aimed to evaluate the effectiveness of a tablet called l spironolactone, in treating acne vulgaris in adult women.
The participants, who had been dealing with facial acne for at least six months and were considered to need oral antibiotics, were randomly assigned to receive either 50 mg/day of spironolactone or a placebo for six weeks, after which time the dose of the medication assigned to the participant was increased to 100 mg/day until week 24.
They were allowed to continue using their usual topical (creams or gels) treatments.
The research is relevant to the healthcare and pharmaceutical industries, particularly those involved in the development and application of acne treatments.